USE OF ADIPOSE-DERIVED PREADIPOCYTES IN BONE DISOREDERS

Information

  • Research Project
  • 6294179
  • ApplicationId
    6294179
  • Core Project Number
    R44AR045856
  • Full Project Number
    2R44AR045856-02
  • Serial Number
    45856
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/28/1999 - 24 years ago
  • Project End Date
    1/31/2003 - 21 years ago
  • Program Officer Name
    MARGOLIS, RONALD N
  • Budget Start Date
    8/1/2001 - 23 years ago
  • Budget End Date
    7/31/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    2
  • Suffix
  • Award Notice Date
    7/23/2001 - 23 years ago
Organizations

USE OF ADIPOSE-DERIVED PREADIPOCYTES IN BONE DISOREDERS

Non-healing bone fractures and periodontal bone loss constitute significant clinical problems with few approved medical options. Bone repair is enhanced by the presence of osteoblasts or osteoblastic precursor cells. Subcutaneous adipose tissue is a plentiful, accessible, and replenishable source of human stromal cells for transplantation. In Phase I of this SBIR, we tested the hypothesis that human adipose tissue-derived stromal cells are capable of osteoblast function. Substantial in vitro data indicates that these stromal cells differentiate into cells biochemically and morphologically similar to osteoblasts. The ability of these cells to form bone in vivo was examined as well. Phase II of this SBIR will extend these in vivo experiments. Specific Aim 1 examines the ability of human adipose tissue-derived stromal cells to form ectopic bone in hydroxyapatite ceramic cubes implanted subcutaneously in immunodeficient mice. Specific Aim 2 explores whether the introduction of a modified bone morphogenetic protein receptor will enhance mineralization by these cells in vitro. Specific Aim 3 will determine if these modified bone morphogenetic protein receptor expressing stromal cells form bone more rapidly and efficiently than control cells using the in vivo murine model described in Aim 1. Together, these studies will provide a strong foundation for pre-clinical experiments in a large animal (canine) fracture repair model. PROPOSED COMMERCIAL APPLICATION: This technology will provide a cost-effective alternative source of stromal cells capable of osteoblast differentiation for autologous and allogeneic transplantation into sites of bone defects and fractures. This has commercial application to orthopedic and periodontal surgical treatments of joint replacement, fracture repair, and bone resorption secondary to tooth decay.

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R44
  • Administering IC
    AR
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    160000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    846
  • Ed Inst. Type
  • Funding ICs
    NIAMS:160000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ARTECEL SCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    DURHAM
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    27713
  • Organization District
    UNITED STATES